A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3574-3582

  Abraham, Jame ^a   Edgerly, Maureen ^b   Wilson, Richard ^d   Chen, Clara ^c   Rutt, Ann ^b   Bakke, Susan ^b   Robey, Rob ^b   Dwyer, Andrew ^c   Goldspiel, Barry ^c   Balis, Frank ^b   Van Tellingen, Olaf ^e   Bates, Susan E ^b   Fojo, Tito ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; KETOCONAZOLE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NAVELBINE; PACLITAXEL; RHODAMINE; TARIQUIDAR; VINCA ALKALOID;

ABDOMINAL PAIN; ADRENAL CANCER; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BLURRED VISION; BREAST CANCER; CANCER PAIN; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DRUG EXPOSURE; DYSPNEA; EWING SARCOMA; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOTENSION; ILEUS; INFECTION; INSOMNIA; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CLEARANCE; LUNG SMALL CELL CANCER; MELANOMA; MONONUCLEAR CELL; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; ORGAN; OVARY CANCER; PAIN; PAROTID GLAND CANCER; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; REMISSION; SEPSIS; SIDE EFFECT; THROMBOSIS; TUMOR; UTERINE CERVIX CANCER; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; P-GLYCOPROTEIN; QUINOLINES; VINBLASTINE; YOUNG ADULT;

EID: 66149192405     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0938     Document Type: Article

References (34)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455:152-162
2. Fojo A, Akiyama S, Gottesman MM, Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 1985;45:3002-3007 (Pubitemid 15007164)
3. Beck WT, Mueller TJ, Tanzer LR. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 1979;39:2070-2076 (Pubitemid 9185002)
4. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58. (Pubitemid 37328807)
5. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, Tariquidar. Cancer Res 2001; 61:749-758
6. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. The molecular interaction of the high affinity reversal agent Tariquidar with P-glycoprotein. Br J Pharmacol 1999; 28:403-411 (Pubitemid 29458600)
7. Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 2007;7:447-459
8. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 1996;32:1070-1081 (Pubitemid 26192988)
9. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995;9:363-382
10. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998;16: 3674-3690 (Pubitemid 28506783)
11. Fisher GA, Lum BL, Hausdorff J, Sikic BI. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996;32: 1082-1088 (Pubitemid 26192989)
12. Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002;94:2333-2343 (Pubitemid 34457113)
13. Robey R, Bakke S, Stein W, et al. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood 1999;93:306-314 (Pubitemid 29019417)
14. van Tellingen O, Kuijpers A, Beijnen JH, Baselier MR, Burghouts JT, Nooyen WJ. Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1992;573:328-332
15. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 2000;6:4186-4191
16. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-984 (Pubitemid 23087894)
17. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 1994;35:510-515 (Pubitemid 24079987)
18. Agrawal M, Abraham J, Balis FM, et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 2003;9:650-656 (Pubitemid 36182597)
19. Labrie P, Maddaford SP, Lacroix J, et al. In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2). Bioorg Med Chem 2007; 15:3854-3868
20. Singh, Sonu S. Preclinical pharmacokinetics: An approach towards safer and efficacious drugs. Current Drug Metabolism. 2006;7:165-182
21. Rowinsky, E. Microtubule-Targeting Natural Products. In Cancer Medicine Kufe D, Bast R, Hait W, Hong W, Pollack R, Weichselbaum R, Holland J, and Frei, E (Editors). 2003; BC Decker Inc. 12(53):436.
22. Bessho Y, Oguri T, Ozasa H, et al. ABCC10/ MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncol Rep 2009; 21:263-268
23. Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2007;48:708-715
24. Lê LH, Moore MJ, Siu LL, et al. Phase I Study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol 2005;56:154-160 (Pubitemid 40884270)
25. Sandler A, Gordon M, DeAlwis DP, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 2004;10:3265-3272 (Pubitemid 38685430)
26. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992;80: 2735-2739
27. Raaijmakers MH. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia 2007;21: 2094-2102 (Pubitemid 47430452)
28. de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 2007;62:214-226 (Pubitemid 46679286)
29. Sikic BI. Multidrug resistance and stem cells in acute myeloid leukemia. Clin Cancer Res 2006;12 (11 Pt 1):3231-3232 (Pubitemid 43910862)
30. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005;45: 872-877 (Pubitemid 41060226)
31. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007;26:1357-1360 (Pubitemid 46328461)
32. Noma K, Naomoto Y, Gunduz M, et al. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines. Oncol Rep 2005;14:645-650
33. Zalcberg JR, Verweij J, Casali PG, et al. EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41: 1751-1757
34. Chu S, Xu H, Shah NP, et al. Detection of BCRABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005;105:2093-2098 (Pubitemid 40731797)